Costa Pierre, Grivel Thierry, Gehchan Naji
Service d'Urologie-Andrologie, Hôpital Caremeau, Nîmes, France;
Patient Prefer Adherence. 2009 Nov 3;3:105-11. doi: 10.2147/ppa.s3937.
Erectile dysfunction (ED) is a prevalent condition that affects men and their partners. Significant improvements in the sexual lives of these couples have been achieved with the introduction of phosphodiesterase 5 (PDE5) inhibitors. A PDE5 inhibitor is now widely recognized as the first-line therapy for the majority of men with ED. Currently, three PDE5 inhibitors - sildenafil, tadalafil and vardenafil - are approved to be taken as needed in anticipation of sexual activity, but only one of these, tadalafil, has been approved to be taken once daily. The primary aims of this review are to summarize the patients' and partners' viewpoints of ED management with PDE5 inhibitors, and to determine whether once-daily tadalafil can contribute to improving some psychological aspects of ED (such as sexual self-confidence, spontaneity and time concerns) compared with on-demand tadalafil or other PDE5 inhibitors taken by patients with ED.
勃起功能障碍（ED）是一种影响男性及其伴侣的常见病症。随着磷酸二酯酶5（PDE5）抑制剂的引入，这些夫妻的性生活有了显著改善。目前，PDE5抑制剂已被广泛认可为大多数ED男性的一线治疗药物。目前，三种PDE5抑制剂——西地那非、他达拉非和伐地那非——被批准可在预期进行性活动时按需服用，但其中只有他达拉非被批准可每日服用一次。本综述的主要目的是总结患者及其伴侣对使用PDE5抑制剂治疗ED的观点，并确定与按需服用他达拉非或其他ED患者服用的PDE5抑制剂相比，每日一次服用他达拉非是否有助于改善ED的某些心理方面（如性自信心、自然度和时间顾虑）。
